Abstract:ID 131403 Poster Board 569 Chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are highly homologous G-protein coupled receptors on the surface of select immune cells with distinct functions and endogenous agonists but with select shared antagonists. These chemokine receptors are promising targets for small molecule therapeutics in the treatment of various cancers and autoimmune diseases, despite only one currently approved therapeutic for CCR5. Rational design of future therapeutics relies on a structural understanding of the determinants of antagonist selectivity as high affinity targeting of only one receptor is often desired. Further complicating therapeutic development, antagonists of human CCR2 (hCCR2) are often inactive to mouse CCR2 (mCCR2). Here, through rationally-guided gain-of-function mutagenesis, we characterized the molecular determinants of CCR2/CCR5 and human/mouse antagonist selectivity. Binding poses for a panel of selective and dual-specific antagonists were generated through molecular docking. Using these poses, we hypothesized that a single bulky residue in TM2 of hCCR5 (Y892.63) and mCCR2 (Y1142.63) dictates selectivity by obstructing binding of the minor pocket-targeting orthosteric antagonists with large substituents. By contrast, the corresponding S1012.63 of hCCR2 is permissive to the binding of such antagonists because it allows them to occupy space otherwise filled by tyrosine. To validate this hypothesis, we introduced a Y892.63S mutation into human CCR5 and tested the ability of a previously CCR2-selective antagonist cherney08a_22 to inhibit chemokine-induced suppression of forskolin-stimulated cAMP in HeLa cells expressing the mutant. Intracellular cAMP levels were measured with the BRET-based CAMYEL reporter. These experiments confirmed that indeed the CCR5(Y892.63S) mutant became sensitive to cherney08a_22 . We also demonstrated how the same residue could impart selectivity against human CCR5 and mouse CCR2 to antagonists with a medium-size (acetamide) substituent. An alternative hypothesis was assessed for CCR2-selective antagonists predicted to bind towards TM5 and the major pocket. Selectivity for these hCCR2 antagonists was suspected to be conveyed by residues F1093.33, S18045.52, or I1985.42 of human CCR5, which are distinct from their CCR2 counterparts. However, the introduction of CCR2-mimicking F1093.33H and S18045.52P mutations in hCCR5 was not sufficient to produce sensitivity to major pocket-targeting CCR2-selective antagonist PF-4136309 . We therefore concluded that its selectivity mechanism is due to the hCCR2 residue R2065.42 which is I1985.42 in hCCR5. Our findings provide a better framework for the rational development of selective and dual-affinity antagonists for CCR2 and CCR5 to overcome past deficiencies in design of potent and selective inhibitors.

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases

Discovery of the First Selective IDO2 Inhibitor As Novel Immunotherapeutic Avenues for Rheumatoid Arthritis

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.

Discovery of 2H-Chromone-4-one Based Sulfonamide Derivatives As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonists.

Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection

Discovery of Chromane-6-Sulfonamide Derivative As a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonist.

Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases

SR16951, a new small molecule antagonist of MCP-1 for the treatment of autoimmune diseases (50.13)

Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer

Abstract 4: Discovery of Novel and Highly Potent Small Molecule Inhibitors of Chemokine Receptor CXCR4

Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity

Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Discovery of Structurally Diverse Natural Product Antagonists of Chemokine Receptor CXCR3

A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist

A fluorescent probe enables the discovery of improved antagonists targeting the intracellular allosteric site of the chemokine receptor CCR7

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

Clinical Significance of Chemokine Receptor Antagonists

Discovery of a First-in-Class GPR183 Antagonist for the Potential Treatment of Rheumatoid Arthritis